Lansoprazole and omeprazole in the treatment of acid peptic disorders

American Journal of Health-System Pharmacy

Volumn 53, Issue 12, 1996, Pages 1401-1415

  Blum, Robert A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Costs; Dosage; Gastrointestinal drugs; Lansoprazole; Omeprazole; Pharmacokinetics; Toxicity; Ulcers

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP;

DRUG COST; DRUG EFFICACY; DUODENUM ULCER; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION; STOMACH MUCOSA; STOMACH ULCER;

EID: 0029889323     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.12.1401     Document Type: Review

References (174)

1. Lampkin TA, Quellet D, Hak LJ et al. Omeprazole: a novel antisecretory agent for the treatment of acid-peptic disorders. DICP Ann Pharmacother. 1990; 24:393-402.
2. Investigational drug brochure. Deerfield, IL: TAP pharmaceuticals; 1991.
3. Nagaya H, Satoh H, Maki Y. Possible mechanisms for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J. Pharmacol Exp Ther. 1989; 252:1289-95.
4. Sachs G, Shin JM, Besancon M et al. The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther. 1993; 7(suppl 1):4-12,29-31.
5. Bell N, Chiba N, Ringham GL et al. Time to maximum effect of lansoprazole on gastric pH in male, normal volunteers. Gastroenterology. 1992; 102:A40. Abstract.
6. Lind T, Cederburg C, Ekenved G et al. Effect of omeprazole - a gastric pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut. 1983; 24:270-6.
7. Tolman KG, Sanders SW, Buchi KN. Gastric pH levels after 15 mg and 30 mg of lansoprazole and 20 mg omeprazole. Gastroenterology. 1994; 106(suppl 4):A172. Abstract.
8. Hongo M, Ohara S, Hirasawa Y et al. Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing. Dig Dis Sci. 1992; 37:882-90.
9. Sanders SW, Tolman KG, Greski PA et al. The effects of lansoprazole, a new H+,K(+)-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther. 1992; 6:359-72.
10. Prichard PJ, Yeomans ND, Mihaly GW et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosages. Gastroenterology. 1985; 88:64-9.
11. Muller P, Dammann GH, Leucht U et al. Human gastric acid secretion following repeated doses of AG-1749. Aliment Pharmacol Ther. 1989; 3:193-8.
12. Blum RA, Hunt RH, Kidd SL et al. Pharmacodynamics of various doses of lansoprazole (lan). Am J Gastroenterol. 1994; 89(suppl 9): 1634. Abstract.
13. Berlin I, Molinier P, Duchier A et al. Dose ranging study of lansoprazole, a new proton pump inhibitor, in patients with high gastric acid secretion. Eur / Clin Pharmacol. 1992; 43:117-9.
14. Pilbrant A, Cederberg C. Development of an oral formulation of omeprazole. Scand J Gastroenterol. 1985; 20:113-20.
15. Moules I, Garrett A, Brocklebank D et al. Gastric acid inhibition by proton pump inhibitor lansoprazole is unaffected by food. Br J Clin Res. 1993; 4:153-61.
16. Vidon N, Dutreuil C, Scoule JC et al. Does lansoprazole influence postprandial digestive function? Aliment Pharmacol Ther. 1993; 7:629-34.
17. Horowitz M, Hetzel DJ, Buckle PJ et al. The effect of omeprazole on gastric emptying in patients with duodenal ulcer disease. Br J Clin Pharmacol. 1984; 18:791-4.
18. Tada M, Murakami A, Karita M et al. Inhibitory effect of AG-1749, a proton pump inhibitor, on gastric secretion; comparison of dose times (after breakfast and before going to bed). Rinsho Seijinbyo. 1991; 21:633-40.
19. Feston HPM, Thijs JC, Lamars CBHW et al. Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. Gastroenterology. 1984; 87:1030-4.
20. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs. 1994; 48:404-30.
21. McTavish D, Buckley M-T, Heel RC. Omeprazole: an updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs. 1991; 42:138-70.
22. Karnes WE, Berlin RG, Maxwell V et al. Prolonged inhibition of acid secretion causes hypergastrinemia without altering pH inhibition of gastrin release in humans. Aliment Pharmacol Ther. 1990; 4:443-56.
23. Lanzon-Miller S, Pounder RE, Hamilton MR et al. 24 Hour intragastric acidity and gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther. 1987; 1:239-52.
24. McCloy RF, Arnold R, Bardhan KD et al. Pathophysiological effects of long-term acid suppression in man. Dig Dis Sci. 1995; 40(suppl):96S-120S.
25. Lechago J, Correa C. Prolonged achlorhydria and gastric neoplasia: is there a causal relationship? Gastroenterology. 1993; 104:1554-7.
26. Rubin W, Mackay R, Jennings D et al. Electron microscopy of gastric oxyntic endrocrine cells in patients treated with lansoprazole for 8 weeks. Am J Gastroenterol. 1992; 87(suppl 9):A1276. Abstract.
27. Iwafuchi M, Watanabe H. Effects of a novel proton pump inibitor AG-1749 (lansoprazole) on endocrine cell populations of human gastric fundic mucosa. Gastroenterol Jpn. 1993; 28:A346. Abstract.
28. Ogoshi K, Kato T, Sato N et al. Clinical study of AG-1749 (lansoprazole): effects on serum gastrin levels and gastric mucosa ECL cell density, etc [in Japanese]. Yakuri Chiryo. 1991; 19:933-46.
29. Brunner G, Arnold R, Fuchs W. Long-term management of acid peptic disease. Paper presented at International Symposium on Lansoprazole. Barcelona, Spain; 1993 Jul 21.
30. Eissele R, Brunner G, Fisher B et al. Evaluation of enterochromaffin-like (ECL)-cell hyperplasia during long-term treatment with the proton pump inhibitor lansoprazole. Gastroenterology. 1993; 104(suppl):A74. Abstract.
31. Solcia E, Rindi G, Havu N et al. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol. 1989; 24(suppl 166):129-37.
32. Freston JW, Borch K, Brand SJ et al. Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells: a review and analysis. Dig Dis Sci. 1995; 40:50S-62S.
33. Marshall BJ. Campylobacter pylori: its link to gastritis and peptic ulcer disease. Rev Infect Dis. 1990; 12:587-93.
34. Iwahi T, Satoh H, Nakao M et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991; 35:490-6.
35. Kozol RA, Dekhne N. Helicobacter pylori and the pathogenesis of duodenal ulcer. J Lab Clin Med. 1994; 124:623-6.
36. McColl KE, Fullarton GM, Chittajalu R et al. Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects. Scand J Gastroenterol. 1991; 26:339-46.
37. Regardh C-G, Gabrielsson M, Hoffman K-J et al. Pharmacokinetics and metabolism of omeprazole in animals and man - an overview. Scand J Gastroenterol. 1985; 20(suppl 108):79-94.
38. Maton PN, Omeprazole. N Engl J Med. 1991; 324:965-75.
39. Delhotal-Landes B, Flouvat B, Duchier J et al. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol. 1993; 45:367-71.
40. Hussein Z, Granneman R, Mukherjee D et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol. 1993; 36:391-8.
41. Andersson T, Cederberg C, Heggelund A et al. The pharmacokinetics of single and repeated once-daily doses of 10, 20, and 40 mg omeprazole as enteric-coated granules. Drug Invest. 1991; 3:45-52.
42. Delhotal-Landes B, Cournot A, Vermerie N et al. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet. 1991; 3:315-20.
43. Tateno M, Nakamura N. Phase I study of lansoprazole (AG 1749) antiulcer agent. Capsule form [in Japanese]. Rinsho Iyaku. 1991; 7:51-62.
44. Tuynman ARE, Festen HPM, Röhss K et al. Lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules. Br J Clin Pharmacol. 1987; 24:833-5.
45. Regardh CG. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol. 1986; 21:99-104.
46. Cederberg C, Andersson T, Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl. 1989; 16:33-40.
47. Karol M, Mukherji D, Eason C et al. The pharmacokinetics of lansoprazole following administration of single doses to subjects with various degrees of renal function. Pharm Res. 1993; 16(suppl 10):S106. Abstract.
48. 14C] omeprazole in patients with impaired renal function. Clin Pharmacol Ther. 1986; 40:344-51.
49. Gustavsson S, Adami HO, Loof L et al. Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial. Lancet. 1983; 2:124-5.
50. Classen M, Dammann H-G, Domschke W et al. Omeprazole heals duodenal but not gastric ulcers more rapidly than ranitidine. Hepatogastroenterology. 1985; 32:243-5.
51. Lauritsen K, Rune SJ, Bytzer P et al. Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. N Engl J Med. 1985; 312:958-61.
52. Prichard PJ, Rubinstein D, Jones DB et al. Double-blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers. Br Med J. 1985; 290:601-3.
53. Bardhan KD, Bianchi-Porro G, Bose K et al. A comparison of two different doses of omeprazole versus ranitidine in treat-ment of duodenal ulcers. J Clin Gastroenterol. 1986; 8:408-13.
54. Bigard MA, Isal JP, Galmiche JP et al. Omeprazole versus cimetidine in short-term treatment of acute duodenal ulcer. Gastroenterol Clin Biol. 1987; 11:753-7.
55. Archambault A, Pare P, Bailey R et al. Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. Gastroenterology. 1988; 94:1130-4.
56. Licht H, Andrieu J, Bognel JC et al. Lansoprazole versus ranitidine dans le traitement des ulcères duodénaux: résultats d'un essai multicentrique contrôlé, randomisé, en double insu sur groupes paralleles. Med Chir Dig. 1990; 19:251-5.
57. McFarland RJ, Bateson MC, Green JRB et al. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. Gastroenterology. 1990; 98:278-83.
58. Mulder CJJ, Schipper DL. Omeprazole and ranitidine in duodenal ulcer healing: analysis of comparative clinical trials. Scand J Gastroenterol. 1990; 25(suppl 178):62-6.
59. Aaronson R, Dorsch E, Padgett C et al. Lansoprazole heals duodenal ulcer. Am J Gastroenterol. 1991; 86(suppl 9):A1307. Abstract.
60. Kager L, Lindberg G, Nilsson LH et al. The effect of omeprazole and ranitidine on ulcer healing, relief of symptoms, and incidence of adverse events in the treatment of duodenal ulcer patients. Hepatogastroenterology. 1991; 38:287-90.
61. Londong W, Barth H, Dammann HG et al. Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. Aliment Pharmacol Ther. 1991; 5:245-54.
62. Takemoto T, Namiki M, Goto Y et al. Studies of clinical usefulness of lansoprazole (AG-1749) in the treatment of gastric and duodenal ulcers: a study of its dosages and administration time. Clin Adult Dis. 1991; 21:995-1013.
63. Valenzuela JE, Berlin RG, Snape WJ et al. U.S. experience with omeprazole in duodenal ulcer: multicenter double-blind comparative study with ranitidine. Dig Dis Sci. 1991; 36:761-8.
64. Delle Fave G, Annibale B, Franceschi M et al. Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease. Aliment Pharmacol Ther. 1992; 6:469-78.
65. Hotz J, Kleinert R, Grymbowski T et al. Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. Aliment Pharmacol Ther. 1992; 6:87-95.
66. Hawkey CJ, Long RG, Bardhan KD et al. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut. 1993; 34:1458-62.
67. Lanza F, Goff J, Scowcroft C et al. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Am J Gastroenterol. 1994; 89:1191-200.
68. Petite JP, Slama JL, Licht H et al. Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer: multicenter double-blind comparative trial [in French]. Gastroenterol Clin Biol. 1993; 17:334-40.
69. Ekström P, Carling L, Unge P et al. Lansoprazole versus omeprazole in active duodenal ulcer: a double-blind, randomized, comparative study. Scand J Gastroenterol. 1995; 30:210-5.
70. Blum AL. Treatment of acid-related disorders with gastric acid inhibitors: the state of the art. Digestion. 1990; 47(suppl 1):3-10.
71. Guyatt GH, Sackett DL, Cook DJ, for the Evidence-based Medicine Working Group. Users' guides to the medical literature: II, How to use an article about therapy or prevention. A. Are the results valid? JAMA. 1993; 270:2598-601.
72. Lauritsen K, Rune SJ, Wulff HR et al. Effect of omeprazole and cimetidine on prepyloric gastric ulcer: double blind comparative trial. Gut. 1988; 29:249-53.
73. Bate CM, Wilkinson SP, Bradby GVH et al. Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer. Gut. 1989; 30:1323-8.
74. Danish Omeprazole Study Group. Omeprazole and cimetidine in the treatment of ulcers of the body of the stomach: a double blind comparative trial. BMJ. 1989; 298:645-7.
75. Walan A, Bader JP, Classen M et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med. 1989; 320:69-75.
76. Takemoto T, Namiki M, Goto Y et al. Clinical evaluation of lansoprazole (AG-1749) for gastric ulcer: a multicenter double-blind comparison with famotidine. Rinsho Seijinbyo. 1991; 21:327-45.
77. Londong W, Hotz J, Kleinert R et al. Lansoprazole in gastric ulcer: a dose finding and comparative trial. Hell J Gastroenterol. 1992; 5:A200. Abstract.
78. Movva R, Sahba B, Jennings D et al. Lansoprazole heals gastric ulcers. Gastroenterology. 1992; 102(suppl 4):A129. Abstract.
79. Schusdziarra V, Rosch T, Grymbowski T et al. Efficacy of lansoprazole in the treatment of gastric ulcer. Hell J Gastroenterol. 1992; 5:A300. Abstract.
80. Florent C, Forestier M, Joubert-Collin M. Lansoprazole versus omeprazole: efficacy and safety in acute gastric ulcer. Gastroenterology. 1993; 104:A80. Abstract.
81. Bardhan KD, Ahlberg J, Hislop WS et al. Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther. 1994; 8:215-20.
82. Michel P, Lemaire M, Colin R et al. Treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial. Aliment Pharmacol Ther. 1994; 8:119-22.
83. 2 receptor antagonists: a controlled clinical trial. Gut. 1991; 32:435-8.
84. Bardhan KD, Dhande DS, Hinchliffe RFC et al. Treatment of ultra refractory duodenal ulcer with omeprazole. Gut. 1988; 29:A724. Abstract.
85. Bardhan KD. Intermittent treatment of duodenal ulcer for long term medical management. Postgrad Med J. 1988; 64(suppl 1):40-6.
86. Delchier J-C, Isal J-P, Eriksson S et al. Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers. Gut. 1989; 30:1173-8.
87. 2-blocker-resistant duodenal ulcer patients. Eur J Gastroenterol Hepatol. 1991; 3:337-42.
88. Brunner G, Arnold R, Hennig U et al. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther. 1993; 7(suppl 1):51-5.
89. 2-receptor antagonist-refractory ulcer: its pathophysiology and treatment. J Clin Gastroenterol. 1991; 13(suppl 1):S129-33.
90. 2-receptor antagonists. Nippon Rinsho. 1992; 50:104-10.
91. Soll AH. Gastric, duodenal, and stress ulcer. In: Sleisenger M, Fordtran J, eds. Gastrointestinal disease: pathophysiology/ s/management. Philadelphia: Saunders; 1993:580-679.
92. Graham DY, Lew GM, Klein PD et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: a randomized, controlled study. Ann Intern Med. 1992; 116:705-8.
93. Sung JJ, Chung SC, Ling TK et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med. 1995; 332:139-42.
94. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA. 1994; 272:65-9.
95. Mohamed A, Chiba A, Wilkerson J et al. Eradication of Helicobacter pylori (Hp): a meta-analysis. Gastroenterology. 1994; 106:A142. Abstract.
96. Tytgat G. Which treatment regimens have been shown to be effective in the eradication of Helicobacter pylori and thus prevented ulcer recurrence? Paper presented at NIH Consen-sus Development Conference on Helicobacter pylori in Peptic Ulcer Disease. Bethesda, MD; 1994 .
97. Mohamed AH, Hunt RH. The rationale of acid suppression in the treatment of acid-related disease. Aliment Pharmacol Ther. 1994; 8:3-10.
98. Unge P, Gad A, Eriksson K et al. Amoxicillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients. Eur J Gastroenterol Hepatol. 1993; 5:325-31.
99. Labenz J, Börsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut. 1994; 35:19-22.
100. Labenz J, Gyenes E, Rühl GH et al. Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol. 1993; 88:491-5.
101. Labenz J, Rühl G, Bertrams J et al. Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol. 1994; 89:726-30.
102. Labenz J, Gyenes E, Rühl GH et al. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut. 1993; 34:1167-70.
103. Pallone F, Luzza F, Delle Fave G et al. Lansoprazole and Helicobacter pylori infection. Clin Ther. 1993; 15(suppl B):49-57.
104. Logan RP, Gummett PA, Schaufelberger HD et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut. 1994; 35:323-6.
105. Harris AW, Gummett PA, Logan RPH et al. Eradication of Helicobacter pylori (Hp) with lansoprazole and clarithromycin. Am J Gastroenterot. 1994; 89:A354. Abstract.
106. Hunt R, Schwartz H, Fitch D et al. Dual therapy of clarithromycin (CL) and omeprazole (OM) for treatment of patients with duodenal ulcers (DU) associated with H. pylori (HP) infection. Gastroenterology. 1995; 108(suppl 4):A118. Abstract.
107. Cayla R, Zerbib F, de Mascarel A et al. High dose of lansoprazole in combination with amoxicillin and clarithromycin twice daily for H. pylori eradication: results of a pilot study. Am J Gastroenterol. 1994; 89:A327. Abstract.
108. De Boer W, Driessen W, Jansz A et al. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet. 1995; 345:817-20.
109. Hosking SW, Ling TKW, Yung MY et al. Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. BMJ. 1992; 305:502-4.
110. Megraud F, Boyanova L, Lamouliatte H. Activity of lansoprazole against Helicobacter pylon. Lancet. 1991; 337:1486. letter.
111. Figura N, Bugnoli M, Armellini D et al. Activities of omeprazole and lansoprazole against Helicobacter pylori in vitro. Hepatogastroenterology. 1994; 41:92-93. Abstract.
112. Nagata K, Takagi E, Tsuda M et al. Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of urease. Antimicrob Agents Chemother. 1995; 39:567-70.
113. McNulty CAM. Bacteriological and pharmacological basis for the treatment of Campylobacter pylori in gastric mucosa. Gastroenterol Clin Biol. 1989; 13:96B-100B.
114. Malanoski GJ, Eliopoulos GM, Ferraro MJ et al. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis. 1993; 12:131-3.
115. 2-receptor antagonists: implications for treatment of Helicobacter pylori infections. Dig Dis Sci. 1991; 39:25-8.
116. Lauritsen K, Andersen BN, Laursen LS et al. Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse: double-blind comparative trial. Gastroenterology. 1991; 100:663-9.
117. Blanchi Porro G, Corinaldesi R, Lazzaroni M et al. Long term treatment with omeprazole 20 mg three days a week or 10 mg daily in the prevention of duodenal ulcer relapse. Aliment Pharmacol Ther. 1994; 8:541-8.
118. Lanza F, Goff J, Silvers D et al. Lansoprazole for one year prevents recurrence of duodenal ulcer. Gastroenterology. 1994; 106:A122. Abstract.
119. Bianchi Porro G, Santalucia F, Petrillo M. Omeprazole v sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Gut. 1990; 31:A1175. Abstract.
120. Bell NJV, Burget D, Howden CW et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992; 51(suppl 1):59-67.
121. Havelund T, Laursen LS, Skoubu-Kristensen E et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. Br Med J. 1988; 296:89-92.
122. Sandmark S, Carlsson R, Fausa O et al. Omeprazole or ranitidine in the treatment of reflux esophagitis: results of a double-blind, randomized, Scandinavian, multicenter study. Scand J Gastroenterol. 1988; 23:625-32.
123. Vantrappen G, Rutgeerts L, Schurmans P et al. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci. 1988; 33:523-9.
124. Dehn TCB, Shepherd HA, Colin-Jones D et al. Double blind comparison of omeprazole (40 mg qd) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux esophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut. 1990; 31:509-13.
125. Bardhan KD, Long R, Hawkey CJ et al. Lansoprazole, a new proton-pump blocker, vs ranitidine in the treatment of reflux erosive esophagitis. Gastroenterology. 1991; 100(suppl 5):A30. Abstract.
126. Dorsch E, Jones J, Padgett C et al. Lansoprazole heals moderate to severe esophagitis. Am J Gastroenterol. 1991; 86(suppl 9):A1294. Abstract.
127. Corallo J, Vicari F, Forestier S et al. Lansoprazole in acute treatment of reflux esophagitis. Gastroenterology. 1993; 104:A58. Abstract.
128. Hatlebakk JG, Berstad A, Carling L et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis: results of a Scandinavian multicentre trial. Scand J Gastroenterol. 1993; 28:224-8.
129. Castell DO, Richter JE, Robinson M et al. Large trial compares lansoprazole to omeprazole. Gastroenterology. 1995; 108:A67. Abstract.
130. Robinson M, Sahba B, Avner D et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 1995; 9:25-31.
131. Ducrotté P, Guillemot F, Elouaer-Blanc L et al. Comparison of omeprazole and famotidine on esophageal pH in patients with moderate to severe esophagitis: a cross-over study. Am J Gastroenterol. 1994; 89:717-21.
132. Rex JC, Andersen HA, Bartholomew LG et al. Esophageal hiatal hernia: a 10-year study of medically treated cases. JAMA. 1961; 178:117-20.
133. Koelz HR, Birchler R, Bretholz A et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology. 1986; 91:1198-205.
134. Feldman M, Harford WV, Fisher RS et al. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K+-ATPase inhibitor: a controlled, double-blind study. Am J Gastroenterol. 1993; 88:1212-7.
135. Sontag S, Kurucar C, Murray S et al. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Gastroenterology. 1992; 102(suppl 4):A167. Abstract.
136. 2-receptor antagonists. Scand J Gastroenterol Suppl. 1989; 166:88-93.
137. Dent J, Yeomans ND, Mackinnon M et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis: a controlled double blind trial of their efficacy and safety. Gut. 1994; 35:590-8.
138. Lundell L, Backman L, Ekström P et al. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol. 1991; 26:248-56.
139. Vigneri S, Termini R, Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995; 333:1106-10.
140. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ et al. Long term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994; 121:161-7.
141. Kahrilas PJ, Hogan WJ. Gastroesophageal reflux disease. In: Sleisenger M, Fordtran J, eds. Gastrointestinal disease: pathophysiology/diagnosis/management. Philadelphia: Saunders; 1993:378-401.
142. Collen MJ, Strong RM. Comparison of omeprazole and ranitidine in treatment of refractory gastroesophageal reflux disease in patients with gastric acid hypersecretion. Dig Dis Sci. 1992; 37:897-903.
143. Sontag S, Schnell T, Kurucar C et al. Lansoprazole heals erosive reflux esophagitis in patients with Barrett's esophagus. Am J Gastroenterol. 1993; 88(suppl 9):A1499. Abstract.
144. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol. 1994; 89:1844-8.
145. Deviere J, Buset M, Dumorceau JM et al. Regression of Barrett's epithelium with omeprazole. N Engl J Med. 1989; 320:1497-8.
146. Gore S, Sutton R, Eyre-Brook IA et al. Regression of columnar epithelium in Barrett's oesophagus with omeprazole. Gut. 1990; 31:A1191-2.
147. Gore S, Healey CJ, Sutton R et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther. 1993; 7:623-8.
148. Jensen RT, Fraker DL. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma. JAMA. 1994; 271:1429-35.
149. Wolfe MM, Jensen RT. Zollinger-Ellison syndrome: current concepts in diagnosis and management. N Engl J Med. 1987; 317:1200-9.
150. Maton PN, Vinayek R, Frucht H et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology. 1989; 97:827-36.
151. Barradell LB, Faulds D, McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs. 1992; 44:225-50.
152. Metz DC, Pisegna JR, Ringham GL et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci. 1993; 38:245-56.
153. Ramdani A, Paul G, Ruszniewski P et al. Comparative efficiency of lansoprazole and omeprazole on 24-hour intragastric pH measurement in 9 cases of Zollinger-Ellison syndrome. Gastroenterology. 1992; 102:A151. Abstract.
154. Clissold SP, Campoli-Richards DM. Omeprazole: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs. 1986; 32:15-47.
155. Colin-Jones DG. Safety of lansoprazole. Aliment Pharmacol Ther. 1993; 7(suppl 1):56-60.
156. Sölvell L. The clinical safety of omeprazole. Digestion. 1990; 47(suppl 1):59-63.
157. Nelis GF. Safety profile of omeprazole: adverse events with short-term treatment. Digestion. 1989; 44(suppl 1):68-76.
158. Sharma BK, Santana IA, Wood EC et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J. 1984; 289:717-9.
159. Colin-Jones DG. Acid suppression: how much is enough? BMJ. 1990;301:564-5.
160. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985; 89:1235-41.
161. Lefebvte RA, Flouvat B, Karolac-Tamisier S et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharrnacol Ther. 1992; 52:458-63.
162. Karol M, Mukherji D, Cavanaugh JH et al. Lack of effect of concomitant multi-dose lansoprazole on single-dose phenytoin pharmacokinetics in subjects. Gastroenterology. 1994; 106(suppl 4):A103. Abstract.
163. 2-receptor antago-nists as clinically important inhibitors of drug metabolism in vitro. Pharmacol Ther. 1987; 33:133-7.
164. Cavanaugh JH, Park YK, Awni WM et al. Effect of lansoprazole on antipyrine and ICG pharmacokinetics. Gastroenterology. 1991; 100(suppl 5):A40. Abstract.
165. Granneman G, Winters E, Locke CS et al. Lack of effect of concomitant lansoprazole on steady-state theophylline pharmacokinetics. Gastroenterology. 1991; 100(suppl 5):A75. Abstract.
166. Howden CW, Reid JL. The effect of antacids and metoclopramide on omeprazole absorption and disposition. Br J Clin Pharmacol. 1988; 25:779-81. Letter.
167. Mirmiran-Yazdy SA, Haber PS, Korsten MA et al. Metabolism of ethanol in rat gastric cells and its inhibition by cimetidine. Gastroenterology. 1995; 108:737-42.
168. Pozzato G, Stebel M, Lunazzi G et al. Influence of acidsecretion blockers on gastric and hepatic alcohol dehydrogenase in rat. Scand J Clin Lab Invest. 1992; 52:747-52.
169. Pozzato G, Franzin F, Moretti M et al. Effects of omeprazole on ethanol metabolism: an in vitro and in vivo rat and human study. Pharmacol Res. 1994; 29:47-58.
170. Hixson LJ, Kelley CL, Jones WN et al. Current trends in the pharmacotherapy for gastroesophageal reflux disease. Arch Intern Med. 1992; 152:717-23.
171. Hillman AL, Bloom BS, Fendrick M et al. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Arch Intern Med. 1992; 152:1467-72.
172. Marks RD, Richter JE, Rizzo J et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology. 1994; 106:907-15.
173. Bate CM. Cost effectiveness of omeprazole in the treatment of reflux esophagitis. Br J Med Econ. 1991; 1:53-61.
174. Walan A, Eriksson S. Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer. Scand J Gastroenterol. 1994; 29(suppl 201):91-7.